Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464891 | 0.85 | GAA (0.33) | GAA | |
| SCHEMBL3466357 | 0.81 | NCF1 (0.38) | CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL3466906 | 0.80 | ALDH1A1 (0.35) | EPHX2EPHX1KDM4E | |
| SCHEMBL27827223 | 0.79 | EPHX2 (0.41) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL11058892 | 0.79 | EPHX2 (0.39) | EPHX2EPHX1CYP1A2TDP1QDPR | |
| SCHEMBL3457860 | 0.78 | EPHX2 (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL27763152 | 0.78 | EPHX2 (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL3130052 | 0.76 | TP53 (0.44) | KDM4ESMN1; SMN2GAA | |
| SCHEMBL2998445 | 0.72 | CYP1A2 (0.44) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL5908925 | 0.72 | GRIK1 (0.37) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | EPHX2 2057/4885EPHX1 1689/4885CYP1A2 1093/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | EPHX2 808/4885EPHX1 299/4885CYP1A2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.